

AF
Patent
Attorney Docket No. 1003301-000914

TFW
\$1653
ce

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	Group Art Unit: 1653
Kjell OLMARKER)	Examiner: ROBERT B. MONDESI
Application No.: 10/092,919)	Confirmation No.: 1488
Filing Date: March 8, 2002)	
Title: NOVEL USE OF CYTOKINE)	
INHIBITORS)	

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a SUPPLEMENTAL Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☐ The fee of 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☒ A statement under 37 C.F.R. § 1.97(e), and the fee of 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☒ Charge \$180.00 to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date July 20, 2006

By:

Benton S. Duffett, Jr.

Benton S. Duffett, Jr.
Registration No. 22030

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Kjell OLMARKER

Application No.: 10/092,919

Filed: March 8, 2002

For: NOVEL USE OF CYTOKINE
INHIBITORS

)
)
) Group Art Unit: 1653

)
) Examiner: ROBERT B. MONDESI

)
) Confirmation No.: 1488

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicant provides information in conformance with 37 C.F.R. §§ 1.97 or 1.98.

This will supplement the earlier Information Disclosure Statement filed on August 26, 2003.

Applicant provides a copy of a June 23, 2006 Official Action (i.e., Communication Pursuant to Article 96(2) EPC) that was issued in the European counterpart (i.e. No. 03 713 135.6-2402) of the present Application.

Copies of documents D1 to D5 previously were submitted with the Information Disclosure Statement filed on August 26, 2003. Applicant now provides a copy of document D6.

Applicant states that document D6 was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The \$180.00 fee pursuant to 37 C.F.R. §1.17(p) is submitted herewith.

To assist the Examiner, the document D6 is listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned once this document is considered.


The further examination and allowance of this application are respectfully requested.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: July 20, 2006

By:


Benton S. Duffett, Jr.
Registration No. 22030


P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application	10/092,919
Filing Date	March 8, 2002
First Named Inventor	Kjell OLMARKER
Examiner Name	Robert B. Mondesi
Attorney Docket No.	1003300-000914

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Black L.E. "Pharmacology review of infliximab BLA" - 21-05-1998-found at internet address:
	http://www.fda.gov/cder/biologics/review/inflcen082498r4.pdf

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.